Cardiovascular Disease is the leading cause of death in the UK, PlaqueTec have developed a Liquid Biopsy System, which allows cardiologists to gain further information from a patient's coronary artery and provide more effective treatment to those affected by the disease.
days to go:
Expired
investment:
£1,493,593
Please watch the video for more information
days to go:
Expired
investment:
£1,210,000
Speeding up access to mental health treatments by using electronic forms and universal communication tools. Thalamos has created a solution for multiple health entities such as the NHS, social services, charities, etc. The company aims to move these entities away from pen and paper, to an easy-to-use online platform, as manual entries are prone to information and data being misplaced, as well as prone to errors.
Thalamos's cloud platform will enable psychiatrists to reduce their clinical and information governance risk, whilst helping to continuously improve their patients' recovery process. The product will be subscription-based from £600 per year, which can be paid monthly and is in-line with other professional services.
days to go:
Expired
investment:
£171,548
Thymia aims to empower clinicians with cutting-edge Neuroscience and AI objectively identify and track mental illness using speech, facial movements and behaviour patterns, enabling personalised, efficient treatment and accurate remote monitoring. They have a large dataset, successful sales, and are raising funds for medical regulation, ADHD expansion, and patent filings.
days to go:
Expired
investment:
£1,126,464
RheEnergise is an energy company that plans to transform pumped hydro technology and boost its capacity with its patented High-Density Hydro (HDH) technology. The company asserts that, by installing HDH on smaller hills and combining it with its HD Fluid R-19, businesses could produce 2.5 times the energy compared to low-density pumped-hydro. RheEnergise aims to install multiple HDH projects to meet the UK's growing energy needs. The company has agreements with entities like SSE, WelshPower, GreenCat Renewables and REG-Power. It is currently using its funding grants of ~£270,000 over the next nine months to build a defendable "Moat" of IP (Patents, Design and copyrights, know-how, and trade secrets) across six critical integrated sub-systems. The company will use the investment received to hire key personnel, progress patents, and accelerate its activities.
days to go:
Expired
investment:
£850,000
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
Mootral is a British Swiss agro-technology company that has come up with its patented natural feed supplement that significantly reduces methane emissions from ruminants by up to 38%. It claims that cow burps are the single biggest source of methane apart from the oil and gas sector. Mootral argues that its product addresses the above issue. The company teamed up with its flagship UK partner, Brades Farm, to provide them with Mootral for their cattle. Mootral has also earned carbon credits from enteric methane reduction from cattle, averaging >70 € per credit. The company intends to use this to finance the cost of its ruminant and help governments around the world reduce their emission targets. It has also received support from the Swiss Climate Foundation and featured in press entities such as CNN and Sky News. The company states it will use the investment to reach 10% of today's almost 1 billion industrialised cattle by 2030, hire key personnel and develop more climate-friendly solutions.
days to go:
Expired
investment:
£1,868,130
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.
days to go:
Expired
investment:
£532,311
Providing convenient and affordable healthcare to patients either at home or their workplace. Practitioners can visit patients and offer a range of medical treatments including vaccinations, testing, physiotherapy and primary care. Qured have been highly successful in London and are growing at an alarming rate, ready to help the whole of the UK.
days to go:
Expired
investment:
£763,160
RootWave is a company that employs electricity to eliminate weeds, providing a sustainable alternative to chemical herbicides for the sake of human health, the environment, and future food production. With global regulators curbing chemical herbicide use due to safety and resistance issues and manufacturers retreating from unprofitable markets due to legal costs, RootWave's patented technology offers improved weed control at a reduced expense compared to herbicides. This approach not only safeguards health but also aids in the ecological restoration of soil, water, and biodiversity, contributing to carbon capture through healthier soils.
days to go:
Expired
investment:
£1,295,810
